semaglutide biosimilar Novo Nordisk readies new obesity treatment after Saxenda < Pharma < Article Semaglutide | GLP-1 Receptor Agonist

Research in animal models has demonstrated that DSIP enhances enkephalin and endorphin signalling the bodys endogenous pain-modulating peptides and is associated with increased pain thresholds

A role for isothiocyanates in plant resistance against the specialist herbivore Pieris rapae

Overview of Clinical Trial in Pediatric Patients WEGOVY injection was evaluated to reduce excess body weight in pediatric patients aged 12 years of age and older with obesity in a 68-week, double-blind, randomized, parallel group, placebo-controlled, multi-center trial in 201 pubertal pediatric patients aged 12 years and older with BMI corresponding to 95th percentile standardized for age and sex (Study 10) (NCT#04102189)

One of those patients accidentally took 20 times the recommended amount